Business
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes.
About this update from Enzolytics Inc.
[{"type":"text","content":"Progress on Sagaliam Acquisition Corp TransactionALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, updated the progress being made on the permit application with the European Medicine Agency (EMA) for the patented immunotherapy ITV-1 treatment of HIV/AIDS virus, for use by patients after receiving chemo and radiation treatment to facilitate recovery from the treatments and those with immunodeficiency.A report has been prepared by the Bulgarian Academy of Science Institute of Organic Chemistry, describing the module 3 clinical trials to be conducted using the Company's ITV-1 therapeutic. The report consists of a description of the research to be performed, the methods for pharmaceutical development of ITV-1 immunotherapy, a technical report of the production process, production control procedures used, analytical procedures, process validation, batch analysis guidelines, characterization of impurities, opening and closing system description and stability expectations. The documentation for the clinical trial will be prepared by Kiwi Farma. A meeting is scheduled in Sofia, Bulgaria on September 19 with the Director of Business Development of CCDR and Development Company, the German company Cooperative Clinical Research and Development (Korporativ Klinik Drug Research and Development) engaged by VIRO to perform the Pharmacokinetic study on the porcine pepsin. Professor, Doctor and Doctor of Medical Sciences, Lachezar Ivanov, will represent the Company in these discussions to identify the specific dates and details regarding the start of clinical trials for the European Medicine Agency.Professor, Doctor and Doctor of Medical Sciences, Lachezar Ivanov, is a valuable member of the VIRO ITV-1 team. Born on August 13,1962 in Sofia Bulgaria, he graduated from Sofia Medical Academy with a medical degree in 1989, obtaining the first specialty of AG. After graduation Dr. Ivanov worked at the Military Medical Academy, where he completed an internship (in all clinical specialties), followed by a specialty in internal medicine. He has also completed courses in ultrasound of abdominal areas and specialty pulmonology. Dr. Ivanov pr...